NEXT-GEN
TREATMENT
Radiotherapeutics
Advances in technology and personalized medicine driving demand for diagnostics and targeted therapeutics using Mo-99 and Lu-177 radioisotopes
Lutetium-177 (Lu-177) is the enabling radioisotope for most of the novel cancer targeting and killing radiotherapeutics biopharma is heavily investing in. Several FDA-approved therapies are in today, and more than 30 are in late stage clinical trials.
Molybdenum-99 (Mo-99) is a critical component used in 80% of the 40 million diagnostic imaging procedures conducted globally each year (50%+ in U.S.) to detect ailments such as heart disease and cancer.
Market Momentum
late-stage radiotherapeutics in clinical trials
0
+
investment from Novartis, Lilly, others
>
0
B+
Radiotherapeutics expected growth over the next 15 years
>
0
% CAGR
2013-2021
FDA approves Xofigo (radium-223)
FDA approves Lutathera
2022-2024
Forms strategic alliance with Bicycle Therapeutics
acquires RayzeBio
Strategic alliances with Aktis Oncology & Radionetics Oncology
Acquires Point Biopharma
Acquires Fusion Pharmaceuticals
Acquires Mariana Oncology
FDA approves Pluvicto
Radioisotope Roadblocks in the U.S.
- North American supplies must come from overseas as there are no domestic producers of Mo-99 and no fully integrated, scaled domestic producers for Lu-177.
- Medical isotopes decay quickly – international shipping, customs, processing, etc. largely eliminates shelf-life in North American hospitals.
- Current production cannot meet the forecasted demand based on medical breakthroughs and drug trials.
- Manufacturers rely on 60+ year-old retrofitted reactors that are non-productive for 40% of the year.
- Scientists, entrepreneurs and industry have been striving to solve this challenge. Problem is – they haven’t.
- Good news: Eden has.